CARD11 MUTATION

CI-VAR-00002635Explore in graph →CIViC 3073

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Diffuse Large B-Cell Lymphoma2
CARD11 MUTATION	(prognostic)	Prognostic	D	Supports Poor Outcome	4	rejected	EID8344 The signalling adaptor CARD11 is required for constitutive NF-kappaB pathway activity and survival in ABC DLBCL. Roughly 10% of ABC DLBCLs have mutant CARD11 isoforms that activate NF-kappaB, but the … (full text at CIViC) PMID 20054396 · Davis et al., 2010 · Open in CIViC	civic
CARD11 MUTATION	(oncogenic)	Oncogenic	E	Supports Oncogenicity	4	submitted	EID11932 This study used a combination of RNA-seq, whole genome and targeted sequencing to identify recurrently mutated genes in follicular and diffuse large B-cell lymphoma. They reported 30 genes that had si… (full text at CIViC) PMID 21796119 · Morin et al., 2011 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Mantle Cell Lymphoma1
CARD11 MUTATION	(oncogenic)	Oncogenic	E	Supports Oncogenicity	3	submitted	EID11844 Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations PMID 27224912 · Wu et al., 2016 · Open in CIViC	civic